Rein Therapeutics to Present at the Guggenheim 3rd Annual Healthcare Innovation Conference
Key Highlights
- ➤Rein Therapeutics (RNTX) CEO Brian Windsor to join Guggenheim healthcare conference fireside chat
- ➤Fireside chat scheduled for November 9, 2026, at 11:00 a.m. ET
- ➤LTI-03 targets alveolar epithelial survival and profibrotic signaling
- ➤LTI-03 received U.S. Orphan Drug and Fast Track designations
Expert Statements
Brian Windsor, President and Chief Executive Officer of Rein Therapeutics
“will participate in a fireside chat at the Guggenheim 3(rd) Annual Healthcare Innovation Conference on Monday, November 9, 2026, at 11:00 a.m. ET”
AUSTIN, Texas, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Rein Therapeutics ("Rein") (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines in orphan pulmonary and fibrosis indications, today announced that Brian Windsor, President and Chief Executive Officer of Rein Therapeutics, will participate in a fireside chat at the Guggenheim 3(rd) Annual Healthcare Innovation Conference on Monday, November 9, 2026, at 11:00 a.m. ET.
A live webcast of the presentation may be accessed via the Investors section of the Rein website at ir.reintx.com. An archived replay of the event will be available on the website for approximately 90 days following the conference.
Get started
Create a free account to read the full story.